Company
Nurix Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein‐degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI‐integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix's dedicated team has built a formidable advantage in translating the science of targeted protein‐degradation into clinical advancements.
Position Summary
This role is located at the interface of Nurix's DEL‐driven drug discovery engine and preclinical drug development platform. The strategic impact of this role is the elucidation and communication of small‐molecule interactions with drug targets to provide mechanistic understanding and guide the design of clinical drug candidates. As a member of the early discovery department, you will make key contributions to validation and characterization of novel chemical matter for our targeted protein‐degradation platform and participate in multiple small and agile teams of drug discovery veterans to achieve discovery and development milestones.
Key Responsibilities
* Design and execute end‐to‐end gene‐to‐structure workflows: construct design, protein engineering, experimental planning, and structure determination.
* Determine high‐resolution structures of protein–ligand and protein complexes using X‐ray crystallography and cryo‐EM.
* Own all aspects of sample preparation, data collection, processing, model building, refinement, and documentation.
* Translate structural findings into actionable insights for project teams and present results to colleagues and senior leadership in written and oral formats.
* Partner with computational chemistry and machine‐learning groups to drive rational drug design and enhance proprietary computational platforms.
* Serve as a structural biology resource across the research organization, providing mechanistic rationale to support project decisions.
* Maintain rigorous laboratory records and contribute to scientific reports, publications, and patent filings.
* Help establish and continuously improve best practices, protocols, and SOPs within the structural biology group.
* Build and maintain deep command of the structural mechanisms of protein ubiquitylation and degradation.
Qualifications
* MS with 8+ years' relevant experience or PhD in structural biology, biochemistry, biophysics, or a related field; 4+ years of hands‐on academic or industry experience. Exceptional entry‐level candidates will also be considered.
* Demonstrated deep expertise in X‐ray crystallography, cryo‐EM, or both. Independent deployment of both technologies is strongly preferred.
* Full proficiency in Phenix, Coot, CryoSPARC, RELION, PyMOL, and Chimera/ChimeraX.
* Exceptional attention to detail, rigorous record keeping, and keen scientific curiosity.
* Strong scientific communication skills with the ability to present complex structural data to diverse, cross‐functional audiences.
* Ability to work strategically, independently, and collaboratively in a fast‐paced, matrix research environment.
Preferred
* Experience in drug discovery or biopharmaceutical setting is highly desirable.
* Experience with protein degrader technologies.
* Working experience with ubiquitin ligases, transcription factors, or membrane proteins.
* Additional skills in SAXS, NMR, HDX‐MS, machine learning, or computational structural biology.
Fit with Nurix Culture and Values
* Collaborative and team‐oriented, eager to share expertise and learn from others.
* Solution‐driven with a hands‐on and resourceful approach.
* Adaptable and comfortable in a fast‐paced, interdisciplinary environment.
* Committed to scientific excellence and the shared goals of the team.
Salary Range
Scientist II: $139,962–$159,890 (plus bonus, equity, and benefits)
Location
Brisbane, CA – Onsite
Nurix is an Equal Opportunity Employer offering a competitive salary and benefits package. Applicants should be legally entitled to work for any employer in the U.S.
#J-18808-Ljbffr